Evaxion with promising results: Danish Biotech Weekly (32)

Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.

In the past week, Evaxion presented promising results for its AI-designed vaccine, Genmab and Synact Pharma announced their Q2 reports, while Ascendis Pharma and Y-mAbs Therapeutics are set to release their Q2 reports this week.

Only 4 of the 20 listed, Danish biotech companies published news the past week. 8 of the 20 companies had a positive development in their share price for the week and 6 companies have had a positive share price performance year to date. Saniona continues to be the best performing stock this year with a price increase of more than 200%.

Company news the past week

Ascendis Pharma

Ascendis Pharma is set to release Q2 earnings on August 8 2023. The current target price from brokerages is $148.27 while the stock trades at $96.79.

Biosergen

No news the past week

Cessatech

No news the past week

CS Medica

No news the past week

Curasight

No news the past week

Evaxion Biotech

Evaxion presents promising results on EVX-B1, an AI-designed vaccine against Staphylococcus aureus(Link)

Evaxion announces financing commitments totaling up to USD 20 million with Global Growth Holding Limited (Link)

Expres2ion

No news the past week

Fluoguide

No news the past week

Genmab

Genmab Announced Financial Results for the First Half of 2023 (Link)

Gubra

No news the past week

Initiator Pharma

No news the past week

IO Biotech

No news the past week

Pila Pharma

No news the past week

Saniona

No news the past week

Scandion Oncology

No news the past week

SynAct Pharma

Synact Pharma published its interim report for Q2 2023 (Link)

ViroGates

No news the past week

Zealand Pharma

No news the past week

Y-mAbs Therapeutics

Y-mAbs Therapeutics is set to announce its Q2 2023 results on August 10

2cureX

No news the past week

SELECTED CASES

SHARE PRICE DEVELOPMENTS

On average, the Danish biotech stocks delivered a negative share price performance last week of -0.7%. Exres2ion Biotech Holding AB became the best performing stock with an 8% increase without announcing any company specific news. Notably, Evaxion Biotech delivered a negative share price return of 4% even though they announced promising results for EVX-B1 against Staphylococcus aureus as well as secured financial commitments of 20 MUSD. The best stocks year-to-date include Curasight, Fluoguide, and Saniona after soaring 81-201%. Overall the Danish biotech stocks are in positive terrotory this year with a year-to-date return of 3.5%.

Read more about Curasight and Fluoguide: The unique cancer treatment of the future – Today’s investment

Overview of share price developments the past week, year-to-date and last twelve months

Disclaimer 

Udvalgte investeringscases

Ønsker du at modtage et af vores nyhedsbreve? Udfyld venligst formularen nedenunder.

  • Investeringscases – Nyhedsbreve med top aktuelle investeringscases fra de nordiske vækstbørser og life science sektoren, og ugentlige markedsopdateringer..
  • Børsnoteringer – Opdateringer på nye og igangværende børsnoteringer i Skandinavien samt resultaterne af dem. (Nyhedsbrev fra Nyemission.dk)   
  • Nyheder – Nyheder fra og om Kapital Partner, herunder indsigt om kapitalmarkederne og børsnoteringer samt invitation til investormøder og- arrangementer.
  • Danish Biotech Weekly – Ugentlig opdatering med nyheder og kursudvikling for alle danske, børsnoterede selskaber uanset hvilket land eller børs de er noteret

*Hvis du ønsker information om vores kommende investeringsforening med fokus på de nordiske vækstbørser, herunder mulighed for at investere, så tilmeld dig nyhedsbrevet Nyheder.




Investornetværk:

Ønsker du at være en del af Kapital Partners investornetværk, hvor du får adgang til investeringer i selskaber og emissioner, samt indbydelse til investorrettede arrangementer
udfyld venligst formularen her.

Udvalgte cases

Del indlægget på sociale media eller på email. 

LinkedIn
Facebook
Twitter
Email